Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vitamin K1
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gland Pharma Receives USFDA Approval for Phytonadione Injectable Emulsion
Details : Phytonadione is indicated for coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2024
Lead Product(s) : Vitamin K1
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Secures US FDA Approval for Latanoprost Ophthalmic Solution
Details : Xalatan-Generic (latanoprost) is a prostanoid FP receptor agonist, small molecule drug candidate, which is indicated for the treatment of open-angle glaucoma or ocular hypertension
Product Name : Xalatan-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives Tentative FDA Approval for Latanoprostene Solution
Details : Latanoprostene bunod is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Product Name : Vyzulta-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : Latanoprostene Bunod
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection
Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.
Product Name : Eribulin Mesylate-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2024
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gland Pharma Launches Generic Cancer Treatment Drug in US
Details : Bortezomib-Generic is therapeutically equivalent to Takeda Pharmaceuticals' Velcade for Injection, is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
Product Name : Bortezomib-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2022
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugammadex Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gland Pharma Receives Tentative Approval for Sugammadex Injection
Details : Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL is generic bioequivalent and therapeutically equivalent to Bridion injection of Merck used to reverse the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to pat...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2021
Lead Product(s) : Sugammadex Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gland Pharma Receives Approval for Generic Foscarnet Sodium Injection
Details : Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir® Injection, 24 mg/mL, of Clinigen Healthcare Limited.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Lead Product(s) : Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable